Oral high-dose glycine administration has been used as an adjuvant treatment for schizophrenia to enhance glutamate neurotransmission and mitigate glutamate system hypofunction thought to contribute to the disorder. Prior studies in schizophrenia subjects documented clinical improvements after 2 weeks of oral glycine administration, suggesting that brain glycine levels are sufficiently elevated to evoke a clinical response within that time frame. However, no human study has reported on brain glycine changes induced by its administration. We utilized a noninvasive proton magnetic resonance spectroscopy ( 1 H-MRS) technique termed echo time-averaged (TEAV) 1 H-MRS, which permits noninvasive quantification of brain glycine in vivo, to determine whether 2 weeks of oral glycine administration (peak dose of 0.8 g/kg/day) increased brain glycine/creatine (Gly/Cr) ratios in 11 healthy adult men. In scans obtained 17 h after the last glycine dose, brain (Gly/Cr) ratios were significantly increased. The data indicate that it is possible to measure brain glycine changes with proton spectroscopy. Developing a more comprehensive understanding of human brain glycine dynamics may lead to optimized use of glycine site agonists and glycine transporter inhibitors to treat schizophrenia, and possibly to treat other disorders associated with glutamate system dysfunction.
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Introduction
Schizophrenia is a brain disorder associated with glutamatergic Nmethyl-D-aspartate (NMDA) system hypofunction (Javitt and Zukin, 1991; Olney and Farber, 1995) . Since glycine enables optimum NMDA receptor activity (Johnson and Ascher,1987; Kleckner and Dingledine,1988; Kessler et al., 1989) , one therapeutic approach to treat schizophrenia has been to administer glycine orally to increase synaptic glycine levels. Early evidence supporting that strategy came from rodent oral glycine administration studies documenting increased brain glycine concentration (Toth and Lajtha, 1981) and glycine-normalized behavior in a phencyclidine (PCP) model of schizophrenia (Toth and Lajtha, 1986) . Subsequent studies in humans with schizophrenia provided clinical support for this approach (Waziri, 1988; Rosse et al., 1989; Costa et al., 1990; Javitt et al., 1994) . High glycine dose (0.8 g/kg/day) studies replicated and extended initial findings by demonstrating improvements in positive, negative, and cognitive symptoms of the disorder (Heresco-Levy et al., 1996 , 1999 , 2004 Leiderman et al., 1996; Javitt et al., 2001 ).
The current literature linking abnormal glutamate neurotransmission to schizophrenia remains active, with a number of studies documenting that the NMDA receptor glycine site is likely to play a role in schizophrenia and its treatment. For example, oral glycineinduced behavioral improvements were reported in a nonhuman primate PCP model of schizophrenia (Linn et al., 2007) . Genetically engineered mice with abnormal glutamatergic NMDA receptor glycine site affinity exhibit aberrant behaviors paralleling some behaviors observed in schizophrenia subjects (Labrie et al., 2008) . In animal models of schizophrenia involving NMDA receptor antagonists, glycine transporter inhibitors can mitigate schizophrenia-like symptoms, improve behavioral deficits, and blunt PCP-induced functional MRI activations (Boulay et al., 2008; Gozzi et al., 2008; Hashimoto et al., 2008; Kanahara et al., 2008; Karasawa et al., 2008) . Together, these findings lend continuing support to the concepts that abnormal glutamate neurotransmission is an important component of schizophrenia and that glycine, an NMDA receptor co-agonist that can augment glutamatergic NMDA receptor neurotransmission (Johnson and Ascher, 1987; Kleckner and Dingledine, 1988; Kessler et al., 1989) , may have therapeutic potential for treating schizophrenia. By contrast, a recent clinical trial documented minimal efficacy for oral high-dose glycine to improve negative symptoms in schizophrenia subjects (Buchanan et al., 2007 ). Yet, the study authors concluded that "it is not 
